Ionis Pharmaceuticals (IONS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS)

IONS 80.40

-1.4%

Jan 9 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: bob zagorin who wrote (4635)	3/1/2011 12:14:43 PM
From: bob zagorin	of 4676

Piper Jaffray Maintains $10 PT, Neutral Rating On ISIS By BenzingaStaffL March 01, 2011 7:28 AM Piper Jaffray is maintaining its $10 PT and Neutral rating on shares of Isis Pharmaceuticals, Inc. (NASDAQ: ISIS). “ISIS ended 2010 with $472 million in cash and guided to end 2011 with >$350 million,” Piper Jaffray writes. “We look for partner Genzyme (now Sanofi-Aventis) to file an MAA with the European Medicines Agency (EMEA) in both Homozygous Familial Hypercholesterolemia (HoFH) and the most severe high cholesterol patients in 1H:11. “ISIS expects to file a BLA in HoFH in the U.S. in 2H:11. Despite a rich pipeline of 24 antisense drugs and a strong balance sheet, we remain Neutral on ISIS as investor focus remains on mipomersen.” Read more: benzinga.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next